OVATION 2

August 27, 2020August 27, 2020

First Ovarian Cancer Patients Dosed in Phase 2 of OVATION 2 Trial

News

The first two patients have been randomized in Phase 2 of the OVATION 2 trial testing the immunotherapy candidate GEN-1 in newly diagnosed advanced ovarian cancer. Celsion Corporation, the immunotherapy’s developer, expects ... Read more

March 25, 2020March 25, 2020

GEN-1 Added to Chemo Improves Removal of Ovarian Tumors, Early Data Show

News

The immunotherapy candidate GEN-1 has shown encouraging results in patients newly diagnosed with advanced ovarian cancer, according to initial results of the OVATION 2 study. Adding GEN-1 to neoadjuvant chemotherapy ... Read more